Bora Pharmaceuticals announced its Q1 2026 consolidated financial results approved by the Board. For the period from January 1 to March 31, 2026, the company reported cumulative operating revenue of TWD 4,001,231 thousand, gross profit of TWD 1,441,258 thousand, and operating income of TWD 407,236 thousand. Net income attributable to owners of the parent was TWD 25,838 thousand, with basic earnings per share (EPS) at TWD 0.21. Total assets stood at TWD 45,331,756 thousand. The net income includes a discontinued operations loss of TWD 14,449 thousand.